Literature DB >> 25672777

High-fat diet combined with low-dose streptozotocin injections induces metabolic syndrome in Macaca mulatta.

Linzhao Li1, Guangneng Liao, Guang Yang, Yanrong Lu, Xiaojiong Du, Jingping Liu, Lan Li, Chengshi Wang, Li Li, Yan Ren, Zhihui Zhong, Jingqiu Cheng, Younan Chen.   

Abstract

Metabolic syndrome (MetS) is associated with abdominal obesity, hyperlipidemia, insulin resistance, and type 2 diabetes mellitus, and increases the risk of cardiovascular disease. Given the complex multifactorial pathogenesis of MetS, qualified animal models are currently seriously limited for researchers. The aim of our study was to develop a MetS model in juvenile rhesus monkeys (Macaca mulatta). Rhesus monkeys (1-year-old) fed a high-fat diet (15 % fat, 2 % cholesterol) were used as the HF group (n = 6), and those on a normal diet (5 % fat) were used as the control group (n = 4). After being fed a high-fat diet for approximately 12 months, 2 monkeys (HF + STZ group) were injected with low-dose streptozotocin (STZ, 25 mg/kg) twice, with a 7 days interval, and were then fed the same diet continuously for another 24 months. After 36 months of treatment, the high-fat diet monkeys, including the HF and HF + STZ groups, had acquired increased body weights, abnormal serum lipids, and impaired glucose tolerance compared to the control group. In addition, much more marked metabolic changes were observed in the two monkeys of the HF + STZ group, particularly in terms of high-blood glucose level and insulin resistance. Morphological observation of biopsies of liver and pancreatic tissues showed decreased islet number and mass and decreased insulin staining in the monkeys of the HF + STZ group. In addition, Oil red O staining suggested remarkable accumulation of lipid droplets in the hepatocytes. Our study suggested that a long-term high-fat diet followed with a low-dose STZ was able to induce MetS in juvenile rhesus monkeys with faster pathophysiological progress compared with high-fat diet induction alone. Our primary data showed that this method may have potentials to develop MetS animal model in non-human primates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25672777     DOI: 10.1007/s12020-015-0542-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  26 in total

1.  A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat.

Authors:  M J Reed; K Meszaros; L J Entes; M D Claypool; J G Pinkett; T M Gadbois; G M Reaven
Journal:  Metabolism       Date:  2000-11       Impact factor: 8.694

Review 2.  Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities.

Authors:  Miriam Cnop; Nils Welsh; Jean-Christophe Jonas; Anne Jörns; Sigurd Lenzen; Decio L Eizirik
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

Review 3.  Dietary fat, genetic predisposition, and obesity: lessons from animal models.

Authors:  D B West; B York
Journal:  Am J Clin Nutr       Date:  1998-03       Impact factor: 7.045

4.  The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.

Authors:  Maria Sörhede Winzell; Bo Ahrén
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

5.  IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.

Authors:  G S Hotamisligil; P Peraldi; A Budavari; R Ellis; M F White; B M Spiegelman
Journal:  Science       Date:  1996-02-02       Impact factor: 47.728

Review 6.  Nutrient regulation of insulin secretion and action.

Authors:  Philip Newsholme; Vinicius Cruzat; Frank Arfuso; Kevin Keane
Journal:  J Endocrinol       Date:  2014-03-25       Impact factor: 4.286

7.  Diet-induced swine model with obesity/leptin resistance for the study of metabolic syndrome and type 2 diabetes.

Authors:  L Torres-Rovira; S Astiz; A Caro; C Lopez-Bote; C Ovilo; P Pallares; M L Perez-Solana; R Sanchez-Sanchez; A Gonzalez-Bulnes
Journal:  ScientificWorldJournal       Date:  2012-05-02

8.  A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet.

Authors:  Xin Zhou; Dewu Han; Ruiling Xu; Suhong Li; Huiwen Wu; Chongxiao Qu; Feng Wang; Xiangyu Wang; Yuanchang Zhao
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

Review 9.  Modeling type 2 diabetes in rats using high fat diet and streptozotocin.

Authors:  Søs Skovsø
Journal:  J Diabetes Investig       Date:  2014-05-19       Impact factor: 4.232

Review 10.  AMPK, insulin resistance, and the metabolic syndrome.

Authors:  Neil B Ruderman; David Carling; Marc Prentki; José M Cacicedo
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

View more
  4 in total

Review 1.  Metabolic Syndrome: Lessons from Rodent and Drosophila Models.

Authors:  Myroslava V Vatashchuk; Maria M Bayliak; Viktoria V Hurza; Kenneth B Storey; Volodymyr I Lushchak
Journal:  Biomed Res Int       Date:  2022-06-22       Impact factor: 3.246

2.  CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies.

Authors:  Jie Ma; Huan Li; Xiangnan Hu; Lu Yang; Qi Chen; Congli Hu; Zhihao Chen; Xiaoyan Tian; Yang Yang; Ying Luo; Run Gan; Junqing Yang
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

3.  Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis.

Authors:  Lu Yang; Wenli Han; Ying Luo; Xiangnan Hu; Ying Xu; Huan Li; Congli Hu; Dan Huang; Jie Ma; Yang Yang; Qi Chen; Yuke Li; Jiahua Zhang; Hui Xia; Zhihao Chen; Hong Wang; Dongzhi Ran; Junqing Yang
Journal:  Front Cell Neurosci       Date:  2018-07-18       Impact factor: 5.505

4.  Proanthocyanidins Ameliorated Deficits of Lipid Metabolism in Type 2 Diabetes Mellitus Via Inhibiting Adipogenesis and Improving Mitochondrial Function.

Authors:  Fangfang Tie; Jifei Wang; Yuexin Liang; Shujun Zhu; Zhenhua Wang; Gang Li; Honglun Wang
Journal:  Int J Mol Sci       Date:  2020-03-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.